Having fewer very fine blood vessels in the fold of skin at the base of the fingernails appears to be linked to an increased risk of clinical worsening in pulmonary arterial hypertension (PAH), a study in the Netherlands suggests. People with chronic thromboembolic pulmonary hypertension (CTEPH) also had…

Treatment with mosliciguat, an inhaled medication given once-daily for pulmonary hypertension (PH), can safely reduce the resistance against blood flow in blood vessels of the lungs, according to a Phase 1 clinical trial. This reduction in pulmonary vascular resistance (PVR) is one of the highest seen in PH…

How chronic thromboembolic pulmonary hypertension (CTEPH) is managed across regions globally varies widely despite treatment advances, a survey study found, highlighting the need for more research, better guidelines, and ongoing education for healthcare providers. The study, “Treatment and management of chronic thromboembolic pulmonary hypertension (CTEPH): A…

Direct oral anticoagulants (DOACs) — a type of blood thinner medication — are as safe and effective as vitamin K antagonists (VKAs), the standard blood thinner used to treat chronic thromboembolic pulmonary hypertension (CTEPH), according to a meta-analysis of published studies. The findings support the use of DOACs as a…

Blood levels of microRNA — small RNA molecules that regulate protein production — are decreased in people with pulmonary embolism (PE) compared with healthy people. PE is the cause of chronic thromboembolic pulmonary hypertension (CTEPH). However, higher blood levels of miR-let7a were found in people with acute PE who…

People with pulmonary hypertension (PH) and high blood acetylcholine (ACh) levels show more severe symptoms and a poorer prognosis than those with lower ACh levels, a single-center study in China suggests. ACh is a neurotransmitter, a chemical messenger that allows nerve cells to communicate…

Two genes were identified as potential drivers of pulmonary arterial hypertension (PAH) in a bioinformatics study, offering opportunities to better understand the disease and explore their use as biomarkers or therapeutic targets. The genes, called WDR43 and GNL2, were more active in the lungs of people with PAH than…

The ARRDC3 gene — implicated in inflammation and cell growth — may be a ferroptosis-related biomarker and treatment target in chronic thromboembolic pulmonary hypertension (CTEPH), according to a new study. Ferroptosis is an iron-dependent type of cell death involved in the damage of lung blood vessels and in lung…

The pulmonary hypertension (PH) community will be busy raising awareness and funds for research this November as they recognize Pulmonary Hypertension Awareness Month.   Leading these efforts is the Pulmonary Hypertension Association (PHA), the country’s oldest and largest nonprofit dedicated to the PH community. The…

The matrix around the heart’s cells does not shrink and may continue to undergo changes after pulmonary endarterectomy, or PEA, a surgery to remove blood clots from the pulmonary arteries that supply the lungs, a small study found. Researchers suggest that fibrosis, or scarring, may explain why the heart’s size…

Treatment with treprostinil improved the risk profile in people with inoperable or persistent severe chronic thromboembolic pulmonary hypertension (CTEPH). The risk profile was assessed using a risk score established to predict a response to treatment and survival in people with pulmonary arterial hypertension (PAH), the most common type…

A Phase 3 clinical trial testing high-dose Opsumit (macitentan) in people with chronic thromboembolic pulmonary hypertension (CTEPH) has ended early after an analysis showed the treatment is unlikely to help patients. The announcement was made in a press release from Janssen, the company that markets Opsumit. Opsumit…